


Powering the Age of Immune Medicine

There is no better diagnostic or therapeutic than your adaptive immune system. We each hold massive diversity of immune cell receptors that stand ready to detect and treat most all diseases in the exact same way. Adaptive Biotechnologies has built a powerful platform to translate the genetic language of these immune receptors, not just in individuals but across the population. And we are using this information to guide the development of better diagnostics and therapeutics for many diseases. Learning how to detect and treat disease like the immune system does naturally has the potential to transform modern medicine, improving human health and quality of life.



LIFE SCIENCE RESEARCH

immunoSEQ®

Sequence immune receptors accurately and at scale

immunoSEQ® T-MAP™

Sequence and map immune receptors to disease-specific antigens

CLINICAL DIAGNOSTICS

clonoSEQ®

Assess minimal residual disease for blood cancer patients

T-Detect™

T cell-based blood test to detect disease

DRUG DISCOVERY

TruTCR®

Identify T-cell receptors for cellular therapy

TruAB™

Identify neutralizing antibodies for therapeutic use

Quick Facts*

FOUNDED
2009

STAFF
600+

STOCK LISTING
ADPT (NASDAQ)

CO-FOUNDERS
Chad Robins
Chief Executive Officer

Harlan Robins
Chief Scientific Officer

LOCATIONS
Seattle, WA
Corporate Headquarters & Clinical Lab

South San Francisco, CA
Cellular Immunology Laboratory

New York, NY
Business Development Office

COMMITTED TO SCIENCE
600+ peer-reviewed publications
our platform fuels advances in immune-driven science & medicine

600+ clinical trials

- **immunoSEQ®** for research in cancer, autoimmune and infectious diseases
- **clonoSEQ®** for research in certain blood cancers
- **T-Detect™** for research in cancer, autoimmune and infectious diseases

clonoSEQ® is available as a FDA-cleared *in vitro* diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ® is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ® including test limitations, please visit clonoSEQ.com/technical-summary.

T-Detect™ COVID is authorized for emergency use under an Emergency Use Authorization to confirm recent or past COVID-19 infection. It is not FDA cleared or approved.

immunoSEQ® and immunoSEQ® T-MAP™ COVID are for Research Use Only. Not for use in diagnostic procedures.

* As of March 2021

Copyright © 2021 Adaptive Biotechnologies Corp. All rights reserved.

adaptivebiotech.com

Enabling Personalized Medicine

Measuring minimal residual disease, or MRD, allows physicians and patients to know if cancer cells are present—and how many. MRD testing provides a personalized way to track an individual’s response to treatment and can help clinicians predict long-term outcomes, assess treatment response, monitor remission status, and detect potential relapse. clonoSEQ is the first and only FDA-cleared clinical diagnostic test for the detection and monitoring of MRD in ALL, multiple myeloma, and CLL patients.

clonoSEQ®

Decoding the Immune System

Across the population, there are trillions of unique T-cell receptors (TCRs) that specifically bind to millions of disease signals (antigens). Now, combining Microsoft’s machine learning and Adaptive’s Immune Medicine Platform, it is possible to create a massive-scale TCR-antigen map that may allow us to decode what an individual’s immune system has fought or is currently fighting. Our goal is to use this map to create a better clinical diagnostic for many diseases—from cancer to autoimmune conditions to infectious diseases. In 2020, through this collaboration, we launched our first indication for T-Detect™: T-Detect COVID, the first and only T cell-based clinical test for COVID and the first-ever clinical test based on TCR sequencing.

Adaptive
biotechnologies™

+

Microsoft

T-Detect™

Personalizing Therapeutics

Using our immune medicine platform, we have identified and characterized more than 3,000+ unique antigen-specific TCRs against 600 different clinically relevant targets. For our first clinical application, together with Genentech, we’re developing, manufacturing, and commercializing novel T-cell therapies for the treatment of a broad range of cancers. We plan to apply our platform to help identify in real time the most promising patient-specific TCRs targeting the patient’s specific cancer antigens to advance the next generation of personalized cellular therapy in oncology.

Adaptive
biotechnologies™

+

Genentech
A Member of the Roche Group

The adaptive immune system is diverse, and the story it tells about each of us is unique. We are decoding these stories to improve lives.



“

We believe that if we can learn to detect and treat diseases like the immune system does naturally, we can transform medicine.”

CHAD ROBINS

Chief Executive Officer
& Co-Founder